Navigation Links
Phase II Of HDL, Inc. Headquarters Expansion Begins This Week
Date:4/17/2013

osciences Commercialization Center was created to assist international life sciences companies locating at the Park with commercialization activities through M&A or IPO, giving these Park's tenants full-scale business assistance as they enter the US market. The Commercialization Center is working with 9 bioscience companies with technologies ranging from medical devices to diagnostics and therapeutics. www.vabiotech.com.

About The Lingerfelt Companies
The Lingerfelt Companies have a proven history of meeting clients' needs and challenges through successful quality real estate solutions backed by over 12 million sq. ft. of development and acquisition valued at over $1 billion. Customizing design and structure to meet each client's specific development requirements, the Lingerfelt Companies specialize in build-to-suit projects, working with the client to exceed their objectives. From initial concept to project completion, the Lingerfelt Companies bring a full range of in-depth planning and a proven track record to every project. www.lingerfeltco.com.

 


'/>"/>
SOURCE HDL, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. 15-Minute Data From Phase 3 Study of Avanafil Featured as a Late Breaking Abstract at SMSNA Annual Meeting
2. Fitzsimons Redevelopment Authority Rolls Out First Phase of Strategic Refocus With Appointment of Four Key Leaders in The Bioscience Industry to Its Board of Directors
3. Webcor Builders Selected as the General Contractor for First Phase of LA BioMeds New Campus Master Plan
4. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
5. S*BIOs Novel JAK2 Inhibitor Pacritinib (SB1518) and Histone Deacetylase Inhibitor Pracinostat (SB939) Demonstrate Promising Activity in Phase 2 Studies for Patients with Myelofibrosis (MF)
6. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
7. Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML to be Presented at the American Society of Hematology
8. Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium
9. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
10. Start of Phase IIa Study in Acute Lung Injury Patients Marks Development Milestone
11. Baxter Initiates Phase I Clinical Trial of Longer-acting Recombinant FVIII Treatment for Hemophilia A
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)...  RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology company ... addressing major unmet medical needs using RNA-targeted technologies, ... Allowance from the United States Patent and Trademark ... for the treatment of fibrosis. The patent covers ...
(Date:1/14/2014)... , Jan. 14, 2014   Kinaxis ®, provider of ... ) and sales and operations planning ( S&OP ) service, ... Biomanufacturing Summit , which will be held at the Hilton ... conference, join Kinaxis customer Elisabeth Kaszas , Director of ...
(Date:1/14/2014)... January 14, 2014 Kerr Corporation, a leading ... and additional how-to information about dual arch impressions on its ... Dual Arch Impressions,” the blog entry serves up a list ... houses a step-by-step demonstration by Dr. David Little as he ...
(Date:1/14/2014)... Independent publisher Bitingduck Press, with offices in Altadena ... ideas for 2014 in production and sales of interactive ... high-quality, low-cost, DRM-free ebooks and to use the sales ... first major development will be bookstore sales in local ...
Breaking Biology Technology:RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2Bitingduck Press Looks Forward to 2014 With Multimedia E-books 2
... (NYSE Amex: CXM ) today announced plans to ... and Drug Administration (FDA) seeking marketing clearance of its ... is an advanced wound care management medical device, which ... by physicians in patients with topical wounds, which include ...
... study from Thomson Reuters released today shows explosive growth in ... rest of the world. , At this pace, China ... The study, Global Research Report: China , informs policymakers ... current place in world science. The study is part of ...
... 1 Pharmasset, Inc. (Nasdaq: VRUS ) today announced ... Association for the Study of Liver Diseases (AASLD) on Monday, ... management will review Pharmasset,s progress on the programs that are ... simultaneous webcast of this event via the internet, log on ...
Cached Biology Technology:Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressure and Venous Ulcers and Other Topical Wounds 2Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressure and Venous Ulcers and Other Topical Wounds 3Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressure and Venous Ulcers and Other Topical Wounds 4China's Research Output More Than Doubled Since 2004, Thomson Reuters Study Reveals 2Pharmasset to Webcast an Investor Event from the AASLD Meeting 2Pharmasset to Webcast an Investor Event from the AASLD Meeting 3Pharmasset to Webcast an Investor Event from the AASLD Meeting 4
(Date:4/24/2014)... play a crucial role in the global-scale cycling ... atmosphere. Now scientists at Scripps Institution of Oceanography ... forward in understanding the microscopic underpinnings of these ... make new cells, a substantial portion of that ... a buffet of edible molecules collectively called "dissolved ...
(Date:4/24/2014)... WEST LAFAYETTE, Ind. - Purdue and West Virginia University ... the golden eagle, providing a bird,s-eye view of eagle ... , Their study calls into question long-held assumptions ... not be as sensitive to ultraviolet light as previously ... have a sharper sense of smell than researchers realized. ...
(Date:4/24/2014)... a commercially important sugar used as a sweetener, ... for synthesizing riboflavin and several antiviral drugs. Genetic ... the bacteria,s ability to produce D-ribose is a ... of this valuable chemical, as described in an ... journal from Mary Ann Liebert, Inc., publishers. The ...
Breaking Biology News(10 mins):Microscopic organism plays a big role in ocean carbon cycling, Scripps scientists discover 2Microscopic organism plays a big role in ocean carbon cycling, Scripps scientists discover 3Genome yields insights into golden eagle vision, smell 2
... program that trains emergency medical service technicians (EMS) to read ... and expedite treatment for the severe heart condition known as ... attack, has excellent results and should become the standard of ... of the Canadian Journal of Cardiology . ...
... cells organized in thousands of small divots. Hit these cells ... candidate for a cancer drug. But a review published this ... argues that these 2D models in fact offer very ... and may often give researchers misleading results. "Up ...
... scientific research has deep roots in the history of ... off spectacularly from launch pads across the disciplines of ... and a sea change in a scientific culture now ... science, crowd-sourced science, DIY research, volunteer monitoring, community participatory ...
Cached Biology News:ECGs administered by paramedics can speed treatment for severe heart attacks 2ECGs administered by paramedics can speed treatment for severe heart attacks 33-D tumor models improve drug discovery success rate 23-D tumor models improve drug discovery success rate 3Inaugural cross-disciplinary Public Participation in Scientific Research conference 2